Oxford University and Moderna to trial pioneering cancer vaccine

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleThe jab targets patients with Lynch syndrome, who are at high risk of developing bowel and ovarian cancer (Alamy/PA) (Local Library)A pioneering cancer vaccine, developed by the University of Oxford and Moderna, is scheduled to undergo trials this summer. The jab targets patients with Lynch syndrome, who are at high risk of developing bowel and ovarian cancer. The study aims to investigate the vaccine’s ability to train the immune system to identify and eliminate pre-cancerous cells in people with Lynch syndrome, aiming to prevent cancer from developing. The initiative represents Moderna's first venture into cancer prevention with its mRNA technology, while Oxford experts believe the approach could be adapted for other cancer types in the future. The initial Intercept-Lynch trial will assess immune responses, optimal dosage, and safety, with a second phase expected to commence in 2027. In fullOxford University and Moderna launch trials of vaccine that could prevent cancerThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in

Raccontata daindependent.co.ukmorningstar.comdailymail.com